Relevant bibliographies by topics / Resistant Tuberculosis

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Resistant Tuberculosis'

Author: Grafiati
Published: 4 June 2021
Last updated: 17 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Resistant Tuberculosis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Resistant Tuberculosis"

1

Bereda, Gudisa. "Medication resistant tuberculosis: multi drugresistant and extensively drug resistant." Journal of Lung, Pulmonary & Respiratory Research 8, no. 4 (2021): 155–58. http://dx.doi.org/10.15406/jlprr.2021.08.00267.

Full text
Abstract:
Medication-resistant tuberculosis is a considerable across-the-board public health challenge that menace’s the substantial advance made in tuberculosis heedfulness and precluding in current decades. Multidrug-resistant tuberculosis is caused by organisms that are resistant to the consummate effective anti-tuberculosis medications (isoniazid and rifampicin). Tuberculosis organisms resistant to the antibiotics used in its treatment are extendedly and happen in entire countries studied. Medication resistance noticed as a sequence of insufficient treatment and once tuberculosis organisms obtain resistance they can disseminate from person to person in the similar way as medication-sensitive tuberculosis. Multidrug-resistant tuberculosis sequences from either infection with organisms which are previously medication-resistant or perhaps advance in the program of a patient's treatment. Rifampicin-resistant tuberculosis is caused by bacteria that do not answered to rifampicin, one of the consummate influential anti- tuberculosis medications. These patients necessitated multidrug-resistant tuberculosis treatment. Extendedly medication-resistant tuberculosis is a figure of tuberculosis caused by organisms that are resistant to isoniazid and rifampicin (i.e. multidrug-resistant tuberculosis) as well as every fluoroquinolone and any of the second–line anti- tuberculosis injectable drugs (amikacin, kanamycin or capreomycin). Extendedly medication-resistant tuberculosis can elaborate when second-line medications are used incorrectly or wrongly managed and upon become ineffective.
APA, Harvard, Vancouver, ISO, and other styles
2

Bereda, Gudisa. "Management of drug resistant tuberculosis: isoniazid resistant, rifampicin resistant, multi drug resistant, and extensively drug resistant." Journal of Lung, Pulmonary & Respiratory Research 9, no. 2 (2022): 46–50. http://dx.doi.org/10.15406/jlprr.2022.09.00279.

Full text
Abstract:
Mycobacterium tuberculosis strains that are resistant to an elevating number of second-line medicines used to treat multidrug-resistant tuberculosis are becoming a threat to public health worldwide. Recent guidelines recommended at least 20 months of treatment, but recent regimens are toxic, poorly tolerated and insufficiently effective, with cure rates as low as 36% and failure rates as high as 50%. The emergence of multidrug-resistant tuberculosis can be defined as strains resistant to at least isoniazid and rifampin has introduced as they are challenging, but overcome the complexities to tuberculosis programs that have responded by treating multidrug-resistant tuberculosis with second-line drugs. Longer multidrug-resistant tuberculosis regimens are treatments for rifampicin resistant tuberculosis or multidrug-resistant tuberculosis which last 18 months or more according to the new 2019 updated World Health Organization drug-resistant tuberculosis guidelines and which may be standardized or individualized. Longer multidrug-resistant tuberculosis regimens are usually designed to involve a minimum number of second-line tuberculosis medicines considered to be effective based on patient history or drug-resistance patterns. The exact number of drugs used to treat extensively tuberculosis drug-resistant is unknown, but most individuals will receive five to six drugs. Identically, as the majority of patients with extensively tuberculosis drug-resistant have been previously treated for multidrug-resistant tuberculosis, prior exposure to drugs like ethionamide and terizidone frequently excludes their use.
APA, Harvard, Vancouver, ISO, and other styles
3

Laskar, Nourjahan, Md Akram Hossain, Jannatul Fardows, and Mominur Rahman. "GeneXpert MTB/RIF Assay for Rapid Identification of Mycobacterium Tuberculosis and Rifampicin Resistance Directly from Sputum Sample." Journal of Enam Medical College 7, no. 2 (2017): 86–89. http://dx.doi.org/10.3329/jemc.v7i2.32653.

Full text
Abstract:
Background: The World Health Organization has endorsed the use of molecular methods for the detection of tuberculosis (TB) and drug resistant TB as a rapid method. In Bangladesh, the Xpert MTB/RIF assay has been implemented into reference laboratories for diagnosis of TB and also MDR TB.Objective: Drug resistant tuberculosis has long been a common problem prevailing in our country. The present study focused on the rapid identification of Mycobacterium tuberculosis as well as drug resistance.Materials and Methods: Sputum samples from a total of 107 cases, assumed as multi-drug resistance tuberculosis, were studied through GeneXpert assay.Results: Out of 107 cases, 91 (85.05%) were detected having M. tuberculosis ? 64 (59.81%) were rifampicin sensitive and 27 (25.23%) were rifampicin resistant. The sensitivity and specificity of the GeneXpert are 87.64% and 75% respectively.Conclusion: GeneXpert assay can be considered for the rapid diagnosis of drug resistant tuberculosis.J Enam Med Col 2017; 7(2): 86-89
APA, Harvard, Vancouver, ISO, and other styles
4

Kiady, Ravahatra, Rakotondrabe Iantsotiana Davidson, Rasoafaranirina Marie Odette, Tiaray Harison Michel, Nandimbiniaina Anjara, and Rakotoson Joëlson Lovaniaina. "Profil De Résistance Des Mycobabcterium Tuberculosis Des Malades En Retraitement Dans La Région De Haute Matsiatra, Madagascar." European Scientific Journal, ESJ 13, no. 18 (2017): 465. http://dx.doi.org/10.19044/esj.2017.v13n18p465.

Full text
Abstract:
Introduction: Relapse, failure and defaulted treatment are a risk factor for Mycobacterium tuberculosis resistance to anti-tuberculosis. The objective of our study is to determine the resistance profile of Mycobacterium tuberculosis of patients in retreatment at the Haute Matriatra area. Method: This is a retrospective, descriptive study carried out on the basis of the data contained in the register of the Haute Matsiatra Regional Tuberculosis Laboratory of the University Hospital of Fianarantsoa, from May 2014 to December 2016 (31 months). We included patients with retreatment in the study. Results: We found 138 patients in retreatment. The average age was 39.32 years with a sex ratio of 2.11. Resistance to Rifampicin and Isoniazid was respectively 2.17% and 2.82%, The prevalence of multidrug-resistant tuberculosis was 0.72%. Conclusion: Tuberculosi resistance, monoresistance or multidrug resistance is a reality in the region of Haute Matsiatra with a prevalence that is still low, reflecting the effectiveness of the tuberculosis control program. However, monoresistances require special attention and monitoring to avoid the emergence of multidrug resistant strains.
APA, Harvard, Vancouver, ISO, and other styles
5

Kaur, Harveen, Dilbag Singh, Amritpal Kaur, N. C. Kajal, and Mukul Sharma. "Central nervous system Tuberculomas in a patient with disseminated multi-drug resistant tuberculosis; A case report." International Journal of Current Research in Medical Sciences 7, no. 1 (2021): 1–5. http://dx.doi.org/10.22192/ijcrms.2021.07.01.001.

Full text
Abstract:
Tuberculosis (TB) is one of the leading causes of death worldwide, particularly in low- and middle-income countries. Although Mycobacterium tuberculosis can involve any organ, most commonly the lung, central nervous system (CNS) tuberculosis is the most devastating form of the disease. Tuberculoma is the most common parenchymal lesion in CNS tuberculosis which could be found in any portion of the intracranial space. The global rates and numbers of drug resistant TB are rising. With increasing globalization, the spread of drug-resistant strains of TB has become a mounting global public health concern. We present a case of 27-year-old male with disseminated multi-drug resistant (MDR) TB who presented with neurological symptoms and multiple CNS Tuberculomas. The patient was started on regimen for Multi-drug resistant tuberculosis (MDR-TB), which allowed the serial resolution of intracranial tuberculomas. Keywords: Tuberculosis (TB), Multi-drug resistant (MDR) TB, Central nervous system (CNS) TB, Tuberculoma, MRI brain
APA, Harvard, Vancouver, ISO, and other styles
6

Diriba, Getu, Habteyes Hailu Tola, Ayinalem Alemu, Bazezew Yenew, Dinka Fikadu Gamtesa, and Abebaw Kebede. "Drug resistance and its risk factors among extrapulmonary tuberculosis in Ethiopia: A systematic review and meta-analysis." PLOS ONE 16, no. 10 (2021): e0258295. http://dx.doi.org/10.1371/journal.pone.0258295.

Full text
Abstract:
Background Drug-resistant tuberculosis and extrapulmonary tuberculosis are the world major public health issues. Although some primary studies have been reported on the burden of drug-resistant tuberculosis in extrapulmonary tuberculosis patients in Ethiopia, there is no systematic review and meta-analysis that attempt to summarize the available literature. Thus, we aimed to estimates the prevalence of drug-resistance in extrapulmonary tuberculosis patients and summarize the risk factors associated with the occurrence of extrapulmonary tuberculosis in Ethiopia. Methods We conducted a systematic review of the published primary studies on extrapulmonary drug-resistant tuberculosis in Ethiopia. Results Eight observational studies were included in this review from different regions of Ethiopia. The overall pooled prevalence of rifampicin resistance was 6% (95% CI 0.03–0.10), while isoniazid resistance was 7% (95% CI 0.03–0.12). The pooled prevalence of multidrug-resistant tuberculosis was 4% (95% CI 0.01–0.07). Previous tuberculosis treatment history and male gender are frequently reported risk factors for developing drug-resistant tuberculosis in extrapulmonary tuberculosis patients. Conclusion The current review has identified a high proportion of resistance to rifampicin, isoniazid, and multidrug-resistant tuberculosis in patients with extrapulmonary tuberculosis in Ethiopia. Clinicians should request drug susceptibility testing for all patients with presumptive extrapulmonary tuberculosis to detect drug-resistance.
APA, Harvard, Vancouver, ISO, and other styles
7

Zahaba, L. M., M. S. Opanasenko, I. V. Liskina, et al. "Drug-resistant pulmonary tuberculosis with surgical treatment: clinical forms, histological and macroscopic aspects." Infusion & Chemotherapy, no. 4 (December 18, 2024): 11–17. https://doi.org/10.32902/2663-0338-2024-4-11-17.

Full text
Abstract:
OBJECTIVE. To clarify the clinical forms of drug-resistant pulmonary tuberculosis with surgical treatment and their relationship with the morphological activity of specific inflammation and the detection of Mycobacterium tuberculosis (MBT) in the surgical material. MATERIALS AND METHODS. The study had a cohort retrospective character. The two groups of patients were studied – with multidrug-resistant tuberculosis (n=27) and pre-extensively drug-resistant tuberculosis (n=25). All patients after completion of a standardized 6-month or individualized chemotherapy was performed surgery. The results of morphological examination namely clarification of pulmonary tuberculosis clinical forms and the morphological degree of activity of a specific inflammatory process were analyzed. A comparative analysis of MBT detection by the cultural method in the surgical material depending on the forms of pulmonary tuberculosis and its degree of activity was performed. RESULTS AND DISCUSSION. Regardless of the drug-resistant profile, different forms of pulmonary tuberculosis were presented in both study groups. In general, cases of multiple tuberculomas (24; 46.2 %) were quantitative prevailed with predominance in group 1. In second place in frequency was diagnosed fibrocaseous tuberculosis (10; 19.2 %) at that cases of pre-extensively drug-resistant tuberculosis (7; 28.0 %) more than twice prevailed. A diagnosis of residual post-tuberculosis changes in the lungs (7; 13.5 %) was at third place, which also prevailed in group 2 (6; 24.0 %). According of morphological examination, it was found that only a quarter of patients at the time of surgery achieved remission of the disease (12; 23.1 %) with a predominance of group 1 (8; 32.0 %). The progression of specific inflammation persisted (18; 34.6 %) in a third of observations in both groups. During surgery operating material was collected for cultural research, which was conducted in 41 cases (78.8 %). In most cases (30; 57.7 %), MBT was not detected, the largest proportion occurred on lung tuberculoma (17; 32.7 %). In almost quarter of all cases, the MBT was detected in surgical material (12; 23.1 %). The share of MBT detection was much higher in fibrocaseous tuberculosis (4; 40.0 %), compared to cases of solitary tuberculomas (4; 16.7 %). The MBT was also detected in residual post-tuberculosis changes – only in the group of pre-extensively drug-resistant tuberculosis (3; 12.0 %). It is established that the morphological activity of the inflammatory process does not clearly correlate with cases of cultural detection of MBT. CONCLUSIONS. The use of modern chemotherapeutic regimens for the treatment of tuberculosis with multidrug resistance and pre-extensively drug-resistant tuberculosis during, in the main course of therapy does not allow to achieve complete abacylation in such patients, which causes additional surgical treatment. In cases of pre-extensively drug-resistant tuberculosis, the development of more severe forms of lung tuberculosis and the lower preoperative effectiveness of specific anti-tuberculosis therapy was observed.
APA, Harvard, Vancouver, ISO, and other styles
8

Ulasi, Amara, Ndubuisi Nwachukwu, Reginald Onyeagba, Solomon Umeham, and Anuli Amadi. "Prevalence of rifampicin resistant tuberculosis among pulmonary tuberculosis patients In Enugu, Nigeria." African Health Sciences 22, no. 2 (2022): 156–61. http://dx.doi.org/10.4314/ahs.v22i2.18.

Full text
Abstract:
Objective: We determined the prevalence of rifampicin resistance in pulmonary tuberculosis patients in Enugu Nigeria.
 Methods: A prospective hospital- based study involving 1300 presumptive multidrug- resistant tuberculosis patients was conducted in Enugu between April 2017 and 31st March, 2019. Participants age ranged from 15 years and older and each submitted one sputum specimens Sputum specimens were analyzed using the Gene Xpert MTB/RIF assay to detect resistance to rifampicin according to manufacturer's protocol.
 Results: The prevalence of rifampicin resistant tuberculosis was 6.8% (95% CI: 5.5- 8.3). Rifampicin resistance was significantly higher in males (9.0%) than females (4.2%) ( P = 0.036< 0.05). Most of the cases were seen in the age group 35-44 years (28.4%). Prevalence of rifampicin resistant tuberculosis was 2.7% in treatment naive (new) patients and 4.1% in patients on anti-tuberculosis therapy (previously treated).
 Conclusion: The prevalence of rifampicin resistant tuberculosis in Enugu was high. Rifampicin resistance in treatment naive (new) patients was also high. This study therefore highlights that active transmission of Multidrug-resistant tuberculosis among young males could be on-going.
 Keywords: Multidrug Resistant Tuberculosis; Rifampicin resistance; Gene Xpert; Drug resistance.
APA, Harvard, Vancouver, ISO, and other styles
9

Ristic, Lidija, Milan Rancic, and Milan Radovic. "Tuberculosis in the 21st century: Challenges, endeavors and recommendations to doctors." Medical review 63, no. 11-12 (2010): 811–15. http://dx.doi.org/10.2298/mpns1012811r.

Full text
Abstract:
The magnitude of problem with tuberculosis lies in the fact that one third of the world population is infected by Mycobacterium tuberculosis. Even in the 21st century, tuberculosis kills more people than any other infective agent. Definition of case of resistance - the case of resistant tuberculosis is precisely defined by the recommendations of the World Health Organization as primary, initial, acquired multidrug resistant and extensively drug resistant tuberculosis. The development of resistance tuberculosis may result from the administration of monotherapy or inadequate combinations of anti-tuberculosis drugs. A possible role of doctors in the development of multi drug-resistant tuberculosis is very important. Actually, multi drug-resistant tuberculosis is a direct consequence of mistakes in prescribing chemotherapy, provision of anti-tuberculosis drugs, surveillance of the patient and decision-making regarding further treatment as well as in a wrong way of administration of anti-tuberculosis drugs. The problem of extensively drug-resistant tuberculosis in the world has become very alarming. In South Africa, extensively drug resistant tuberculosis accounts for 24% of all tuberculosis case. It can be concluded that only adequate treatment according to directly supervised short regiment for correctly categorized cases of tuberculosis can stop the escalation of multidrug or extensively drug resistant tuberculosis, which is actually an incurable illness in the 21st century.
APA, Harvard, Vancouver, ISO, and other styles
10

Ramachandra, Venkateswari, Usharani Brammacharry, Aaina Muralidhar, et al. "Assess the Diagnostic Accuracy of GeneXpert to Detect Mycobacterium tuberculosis and Rifampicin-Resistant Tuberculosis among Presumptive Tuberculosis and Presumptive Drug Resistant Tuberculosis Patients." Microbiology Research 15, no. 1 (2023): 91–108. http://dx.doi.org/10.3390/microbiolres15010006.

Full text
Abstract:
GeneXpert MTB/RIF is a rapid molecular diagnostic tool capable of simultaneously detecting Mycobacterium tuberculosis and rifampicin resistance. This study aimed to assess the diagnostic precision of GeneXpert MTB/RIF assay to detect pulmonary and extrapulmonary tuberculosis and evaluate the performance for detecting of rifampicin resistance. Of 37,695 samples, 7156 (18.98%) were tuberculosis-positive, and 509 (7.11%) were rifampicin-resistant. The sensitivity, specificity, positive predictive value, negative predictive value, disease prevalence, and accuracy of the GeneXpert MTB/RIF assay for pulmonary tuberculosis were 99.87% (95%CI: 99.75–99.94), 99.92% (95%CI: 99.88–99.95), 99.71% (95%CI: 99.54–99.82), 99.97% (95%CI: 99.93–99.98), 21.38% (95%CI: 20.92–21.86), and 99.91% (95%CI: 99.87–99.94), respectively. For extrapulmonary tuberculosis, the sensitivity, specificity, PPV, NPV, disease prevalence, and accuracy of GeneXpert MTB/RIF assay accounted for 99.45% (95%CI: 98.73–99.82), 99.84% (95%CI: 99.73–99.92), 98.70% (95%CI: 97.73–99.25), 99.93% (95%CI: 99.84–99.97), 10.64% (95%CI: 9.99–11.31), and 99.80% (95%CI: 99.68–99.88), respectively. Despite its high sensitivity for detecting tuberculosis and rifampicin resistance, GeneXpert MTB/RIF had contradictory results for 20.5% of cases among patients with smear-negative results and 54.9% of cases among patients with a high risk of multidrug-resistant tuberculosis. Of 46% fluoroquinolone-resistant cases, 16.56% (26/157) were multidrug-resistant tuberculosis isolates, and 4.02% (20/498) were isoniazid-resistant, a characteristic distribution leading to about 17.2% of fluoroquinolone-resistance events and relevant marker gyr-A mutations in MDR tuberculosis isolates. Further, our study indicated that increased fluoroquinolone resistance among rifampicin-resistant and isoniazid-resistant tuberculosis endangers the success of newly endorsed MDR-TB regimens.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Resistant Tuberculosis"

1

Seddon, James Alexander. "Drug-resistant tuberculosis in children." Thesis, London School of Hygiene and Tropical Medicine (University of London), 2012. http://researchonline.lshtm.ac.uk/4646555/.

Full text
Abstract:
The number of children globally who develop drug-resistant tuberculosis is unclear, in part due to diagnostic challenges and limited resistance testing, and in part because recording and reporting is not comprehensive. Large numbers of children, however, are exposed to drug resistant bacilli each year and it is clear that the very young and those immune-compromised are vulnerable to developing disease. Few studies have looked at the progression from exposure to infection or from infection to disease in the child contacts of adults with drug-resistant tuberculosis. It is uncertain which factors influence this progression and also whether any interventions can prevent it. Finally, few studies have analysed the presentation, treatment and outcome of children with disease. This thesis starts by reviewing what is published regarding drug-resistant tuberculosis in children. This includes systematic reviews of the management of children exposed to drug resistant tuberculosis as well as the management of those with multi drug-resistant tuberculosis disease. It reviews what is known regarding the second-line tuberculosis drugs in children and then clarifies the definitions that are used throughout the rest of the work. The thesis then systematically examines each of the stages from infection to disease with a series of inter-related studies. The first study attempts to quantify the burden of drug resistance in the context that the work is carried out. The following study investigates the risk factors for infection and prevalent disease in children exposed to a multi drug-resistant tuberculosis source case. This is followed by two studies which explore the transmission of drug-resistant bacilli from adults to children. The identification and referral patterns and obstacles to referral for exposed children are examined through operational studies that include qualitative and quantitative components. A descriptive cohort study assesses the toxicity and efficacy of a standardised preventive treatment regimen given to child contacts. The final part of the thesis includes a series of studies to investigate the treatment of drug resistant tuberculosis disease in children and the adverse effects of the second-line medications.
APA, Harvard, Vancouver, ISO, and other styles
2

Krüüner, Annika. "Drug-resistant Mycobacterium tuberculosis in Estonia /." Stockholm, 2003. http://diss.kib.ki.se/2003/91-7349-455-0/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Patel, Fadheela. "Development of a cost-effective drug sensitivity test for multi-drug resistant and extensively drug-resistant tuberculosis." Thesis, Cape Peninsula University of Technology, 2010. http://hdl.handle.net/20.500.11838/1496.

Full text
Abstract:
Thesis (MTech (Biomedical Technology))--Cape Peninsula University of Technology, 2010<br>The World Health Organisation estimates that nine million people are infected with tuberculosis (TB) every year of which ninety-five percent live in developing countries. Africa has one of the highest incidences of TB in the world. but few of its countries are equipped to diagnose drug-resistant TB. This study aimed to develop a robust. yet simple and cost-effective assay. which would require minimal sophisticated instrumentation and specialised personnel that would make drug sensitivity screening for multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) accessible to resource-poor high-burden settings. A four-quadrant colorimetric agar plate method was developed which showed good specificity (97.3%-100%) and sensitivity (77.8%-100%) compared to the polymerase chain reaction (PCR) method used as gold standard. Agreement between the methods. using Simple Kappa Coefficients. ranged between very good and excellent. all with high statistical significance (P < 0.0001). The currently used BACTEC MGIT SIREN sensitivity assay coupled with the E-test® strip method. as routinely used in the TB reference laboratory. was compared and showed excellent comparison with the newlydeveloped plate method. for each antibiotic tested. as well as the resultant monoresistant, MDR- or XDR-TB diagnoses. Moreover. the new method was found to be extremely cost-effective. priced at half the cost of a peR assay. These four quadrant plates. with a colorimetric indicator and selected antibiotics. can be considered as an economic altemative or a complimentary method for laboratories wishing to reduce the cost and complexity for TB drug sensitivity testing. Routine diagnostic testing would thus be made more accessible and affordable to laboratories that are not presently diagnosing drug resistant TB. therefore enhancing case detection and treatment in the resource-poor settings hardest hit by this curable disease.
APA, Harvard, Vancouver, ISO, and other styles
4

MEDEIROS, Nilma Maria Pôrto De Farias Cordeiro De. "Caracterização da tuberculose resistente no estado da Paraíba entre 2003 e 2013." Universidade Federal de Pernambuco, 2015. https://repositorio.ufpe.br/handle/123456789/17759.

Full text
Abstract:
Submitted by Irene Nascimento (irene.kessia@ufpe.br) on 2016-08-26T18:01:43Z No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) NILMA MEDTROP VD.pdf: 2060397 bytes, checksum: 801ad4896a8a5f3c544547167d27652d (MD5)<br>Made available in DSpace on 2016-08-26T18:01:43Z (GMT). No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) NILMA MEDTROP VD.pdf: 2060397 bytes, checksum: 801ad4896a8a5f3c544547167d27652d (MD5) Previous issue date: 2015-02-05<br>A tuberculose (TB) é a doença mais comum da humanidade. Atualmente, a Organização Mundial de Saúde estimou nove milhões de novos casos e um milhão e meio de mortes decorrentes da doença. A rápida expansão da resistência aos fármacos antituberculose tem prejudicado o controle global da TB, constituindo um grave problema de Saúde Pública. No Brasil, a semelhença de outros países endêmicos, tem-se observado uma variabilidade na prevalência de resistência e no estado da Paraíba (PB) não há dados recentes e concisos. Dessarte, esse estudo objetivou verificar a prevalência de resistência do Mycobacterium tuberculosis aos fármacos do esquema de primeira linha do tratamento da TB utilizados no Brasil e a frequência de fatores de risco - sexo, idade, tratamento prévio e ingesta alcóolica - em pacientes adultos com diagnóstico de TB pulmonar resistente (TBP), atendidos em serviço de referência na PB durante o período de 01 de janeiro de 2003 a 31 de dezembro de 2013. Para obtenção dos dados, utilizou-se formulário padronizado, preenchido, retrospectivamente, a partir das informações contidas nos prontuários dos pacientes atendidos no período do estudo. Foram notificados 69 casos, com prevalência de 0,5%. Evidenciou-se 17,4% de mono, 14,5% de poli e 68,1% de multirresistência. A resistência à isoniazida (INH) mostrou-se importante, tanto isolada, quanto em associações; bem como e, principalmente, a TB multirresistente (TBMR). Perante os fatores de risco, o sexo masculino (73,9%), a faixa etária de 40 a 49 anos (46,4%), a realização de tratamento prévio (98,5%) e a ingesta alcóolica (57,4%) foram os de maior ocorrência. Todavia, não expressaram significância estatística no estudo realizado tendo a PB como cenário. O desfecho foi a cura para 44,9% dos casos; no entanto, o abandono ao tratamento foi considerável, principalmente para a TBP monorresistente (33,3%). As características sociodemográficas compreenderam: a cor da pele parda (68,5%), o estado civil casado (50,9%), o nível de instrução até o fundamental (67,3%) e a procedência do interior da PB (78,2%). Quanto à coinfecção com HIV/AIDS, ocorreu em 14,5%; no entanto, nesse grupo a TBMR, também, foi mais frequente. Desta feita, mais estudos são imprescindíveis no intuito de investigar genotipicamente a resistência da TB no estado da PB, visto que alguns estudos genéticos têm reportado mutações em cepas resistentes à rifampicina (RMP), estando associada a maior transmissibilidade e a resistência à INH tem sido associada com mutações de vários genes. Assim, correlacionando com outros estados e países a fim de colaborar com o enfrentamento da doença na busca do controle e cura extensiva a todos. Por outro lado, há necessidade de fortalecimento das ações do programa de controle da TB, tanto em nível estadual, quanto nos municípios.<br>Tuberculosis (TB) is the most common disease of humanity. Currently, the World Health Organization estimated nine million new cases and a million and a half deaths from the disease. The rapid spread of resistance to antituberculosis drugs has undermined the global TB control, constituting a serious public health problem. In Brazil, as other endemic countries, it has been observed variability in the prevalence of resistance and the state of Paraíba (PB) no recent and accurate data. Thus, this study aimed to determine the prevalence of resistance of the Mycobacterium tuberculosis to first-line drugs in TB treatment regimen used in the Brazil and frequency of risk factors - gender, age, prior treatment and alcoholic intake - in adults patients diagnosed with resistant pulmonary TB (PTB), treated on reference service in PB during the January 1, 2003 to December 31, 2013. To obtain the data, it used standardized form filled out retrospectively from the information contained in the medical records of patients seen during the study period. Were reported 69 cases, with a prevalence of 0.5%. Revealed a 17.4% to mono, 14.5% to poly and 68.1% to multidrug resistance. The isoniazid (INH) resistance was found to be important, both isolated, as in associations; as well as, and especially multidrug resistant TB (MDR-TB). In view of the risk factors, males (73.9%), the age group 40 -49 years (46.4%), the realization of previous treatment (98.5%) and alcoholic intake (57.4%) were the most frequent. However, did not express statistical significance in the study with the PB as a scenario. The outcome was the cure for 44.9% of cases; however, abandon to treatment was significant, particularly for mono resistant PTB (33.3%). The sociodemographic characteristics included: dark brown skin (68.5%), married status (50.9%), level of education up to primary (67.3%) and the origin from the interior of PB (78.2%). The co-infection with HIV/AIDS occurred in 14.5%; however, this group the MDR-TB also was more frequent. This time, more studies are essential in order to investigate genotypically the TB resistance in the state of PB, as some genetic studies have reported mutations in strains resistant to rifampicin (RMP) and are associated with increased transmissibility and INH resistance has been associated with mutations multiple genes. Thus, correlating with other states and countries to collaborate with coping with the disease in the search of control and extensive cure to all. On the other hand, there is need to strengthen the actions of the TB control program at the state level and in the municipalities.
APA, Harvard, Vancouver, ISO, and other styles
5

Hayes, Cindy. "Prevalence and resistance gene mutations of multi-drug resistant and extensively drug resistant mycobacterium tuberculosis in the Eastern Cape." Thesis, Nelson Mandela Metropolitan University, 2014. http://hdl.handle.net/10948/d1020374.

Full text
Abstract:
The emergence and spread of multi-drug resistant (MDR-TB) and extensively drugresistant tuberculosis (XDR-TB) are a major medical and public problem threatening the global health. The objectives of this study were to (i) determine the prevalence of MDR-TB and XDR-TB in the Eastern Cape; (ii) analyze patterns of gene mutations in MDR-TB and (iii) identify gene mutations associated with resistance to second line injectable drugs in XDR-TB isolates. A total of 1520 routine sputum specimens sequentially received within a period of 12 months i.e. February 2012 to February 2013 from all MDR-TB and XDR-TB patients treated by Hospitals and clinics in the Eastern Cape were included in this study, of which 1004 had interpretable results. Samples were analyzed with the Genotype MTBDRplus VER 2.0 assay kit (Hain Lifescience) for detection of resistance to Rifampicin and Isoniazid while solid and liquid culture drug susceptibility tests were used for ethambutol, streptomycin, ethionamide, ofloxacin, capreomycin and amikacin. PCR and sequence analysis of short regions of target genes gyrA, (encode subunit of DNA topoisomerase gyrase), rrs (16S rRNA) and tlyA (encodes a 2’-O-methyltransferase) were performed on 20 XDR-TB isolates. MTBDRplus kit results and drug susceptibility tests identified 462 MDR-TB, 284 pre-XDR and 258 XDR-TB isolates from 267 clinics and 25 hospitals in the Eastern Cape. There was a high frequency of resistance to streptomycin, ethionamide, amikacin, ofloxacin and capreomycin. Mutation patterns indicated differences between the health districts as well as differences between the facilities within the health districts. The most common mutation patterns observed were: (i) ΔWT3, ΔWT4, MUT1 [D516V+del515] (rpoB), ΔWT, MUT1 [S315T1] (katG), ΔWT1 [C15T] (inhA) [39 MDR, 204 XDR-TB and 214 pre XDR-TB isolates], (ii) ΔWT8, MUT3 [L533P+S531L] (rpoB), ΔWT, MUT1 [S315T1] [145 MDR, 18 pre-XDR and 3 XDR-TB solates] and (iii) ΔWT3, WT4 [D516Y+del515] (rpoB), ΔWT, MUT1 [S315T1] (katG) [75 MDR, 1 pre-XDR and 7 XDR-TB isolates]. Mutations in inhA promoter regions were strongly associated with XDR-TB isolates. Two thirds (66.6 percent (669/1004) of the isolates had inhA mutations present with 25.4 percent (170/669) found among the MDR isolates, 39.2 percent (262/669) among the pre-XDR isolates and 35.4 percent (237/669) among the XDR-TB isolates, which implies that these resistant isolates are being spread by transmission within the community and circulating in the province. There was good correlation between XDR-TB drug susceptibility test results and sequence analyses of the gyrA and rrs genes. The majority of XDR-TB isolates contained mutations at positions C269T (6/20) and 1401G (18/20) in gyrA and rrs genes respectively. Sequence analysis of short regions of gyrA and rrs genes may be useful for detection of fluoroquinolone and amikacin/ kanamycin resistance in XDR-TB isolates but the tlyA gene is not a sensitive genetic marker for capreomycin resistance. This study highlighted the urgent need for the development of rapid diagnostics for XDR-TB and raised serious concerns regarding ineffective patientmanagement resulting in ongoing transmission of extremely resistant strains of XDRTB in the Eastern Cape suggesting that the Eastern Cape could be fast becoming the epicenter for the development of Totally Drug-resistant Tuberculosis (TDR-TB) in South Africa.
APA, Harvard, Vancouver, ISO, and other styles
6

Ko, Wai-ting, and 高慧婷. "Molecular characterization of pyrazinamide resistance in Mycobacterium tuberculosis." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/193536.

Full text
Abstract:
Tuberculosis (TB) is a highly infectious disease that causes the second highest mortality rate in human worldwide. The emergence of multi-drug resistance tuberculosis (MDR-TB) leads to a major public health problem in controlling TB-caused mortality. Pyrazinamide (PZA) is an important first-line drug in the treatment of MDR-TB. However, since the challenge in performing susceptibility test on PZA, World Health Organization has not published any data on the prevalence of PZA resistance in Mycobacterium tuberculosis (M. tuberculosis). Since the occurrence of PZA resistance makes MDR-TB more difficult to treat with poor prognosis, rapid detection method in PZA resistance is urgently needed. Since pncA mutation is highly associated with up to 98% PZA resistant M. tuberculosis strains, it is worthwhile to develop rapid molecular method for detecting PZA resistance. This study aims to identify the mutations in PZA resistant M. tuberculosis strains. The first part of this study aims to characterize the pattern of pncA mutation among PZA-resistant and PZA-susceptible M. tuberculosis using Sanger sequencing method. Among all clinical isolates, 12 out of 29 cases of M. tuberculosis were resistant to PZA. All PZA-resistant M. tuberculosis strains harbored pncA mutation, whereas no known mutations were found among those PZA-susceptible strains, giving the positive predictive value to be 100%. Eight mutation patterns were found among 12 resistant isolates. Four of these pncA mutations have not been described previously by other studies. Study also characterizes the pattern of pncA mutation in 19 sputum specimens, with 2 mutation patterns found. Overall 10 mutation patterns were found in this study. Results show that the mutation of pncA gene is highly associated with PZA-resistant M. tuberculosis. Results also suggest the scattered and more extensive mutations in pncA gene that confer PZA resistance to M. tuberculosis. The second and the last part of this study aims to evaluate the possibility of using molecular method to detect PZA resistance in routine clinical laboratory. Results show that using molecular sequencing to detect PZA resistance can shorten the turnaround time to about 3-4 working days. Since mutation of pncA was scattered along the entire pncA gene, using DNA sequencing approach may be the best strategy for the rapid detection of PZA resistance in M. tuberculosis.<br>published_or_final_version<br>Medical Sciences<br>Master<br>Master of Medical Sciences
APA, Harvard, Vancouver, ISO, and other styles
7

Dubiniecki, Christine. "Drug resistant tuberculosis in Montreal 1992-1995." Thesis, McGill University, 2001. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=33751.

Full text
Abstract:
Objective. Since the 1980's the incidence of tuberculosis (TB) in Montreal has remained at 11 cases per 100,000. In order to improve TB prevention and control programs, we sought to identify predictors of tuberculosis drug-resistance and to describe the epidemiology of TB drug resistance on the island of Montreal.<br>Study design. Retrospective descriptive analysis Study population. All culture proven TB patients reported to the Montreal Regional Health Board aged 0--49 for 1992--1994 and 0--18 years for 1995.<br>Results. Drug resistant TB was found in 18.3% of culture-proven TB cases. The rate of INH resistance in our study cohort was 10.6%. Two percent of TB cases were found to have MDR-TB. Only 3 TB cases (0.9%) in our study cohort developed acquired drug resistance over the study period. Previous history of TB was associated with a 3.9 times greater risk of drug resistant TB.<br>Conclusions. Drug resistance is a significant problem in Montreal that continues to hinder TB treatment and control. Previous history of tuberculosis is a strong predictor of drug resistance. In addition, immigration from individual countries was not associated with an increase in the rate of drug resistance. Nonetheless, country-specific drug resistance rates may serve to predict the likelihood of drug resistant TB among the foreign-born in Canada.
APA, Harvard, Vancouver, ISO, and other styles
8

Leung, Oi-chi Anna, and 梁愛枝. "Molecular characterization of ofloxacin resistant mycobacterium tuberculosis." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B45010122.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ford, Christopher Burton. "The Evolution of Drug Resistant Mycobacterium Tuberculosis." Thesis, Harvard University, 2012. http://dissertations.umi.com/gsas.harvard:10596.

Full text
Abstract:
Mycobacterium tuberculosis (Mtb) poses a global health catastrophe that has been compounded by the emergence of highly drug resistant Mtb strains. We used whole genome sequencing (WGS) to directly compare the accumulation of mutations in Mtb isolated from cynomolgus macaques with active, latent and early reactivation disease. Based on the distribution of single nucleotide polymorphisms (SNPs) observed, we calculated the mutation rates for these disease states. Our data suggest that during latency, Mtb acquires a similar number of chromosomal mutations as would be expected to emerge in a logarithmically growing culture over the same period of time despite reduced bacterial replication during latent infection. The pattern of polymorphisms suggests that the mutational burden in vivo is due to oxidative DNA damage. We next sought to determine why some strains of Mtb are preferentially associated with high-level drug resistance. We demonstrate that Mtb strains from the East Asian lineage acquire drug resistances in vitro more quickly than Mtb strains from the Euro-American lineage. Their higher drug resistance rate in vitro reflects a higher basal mutation. Moreover, the in vitro mutation rate correlates well with the bacterial mutation rate in humans as determined by whole genome sequencing of clinical isolates. Finally, using an agent-based model, we show that the observed differences in mutation rate predict a significantly higher probability of multi-drug resistance in patients infected with East Asian lineage strains of Mtb. Lastly, we sought to determine the mechanisms Mtb uses to proofread nascently polymerized DNA. Through fluctuation analysis of deletion mutants of two potential \(polIII\epsilon\) homologs, we demonstrate that neither is responsible for the maintenance of DNA replication fidelity. To explore the possibility that one of these homologs, Rv3711c, participates in an unknown redundant pathway, we used transposon capture and sequence (TraCS) to identify genes conditionally essential in an Rv3711c deletion mutant. Our analysis suggests that while Rv3711c does not participate in proofreading, it may act in an alternative novel DNA repair pathway. Taken together, our fluctuation analysis and TraCS data suggest that mycobacteria do not use canonical methods of proofreading to maintain genomic fidelity.
APA, Harvard, Vancouver, ISO, and other styles
10

Yeremenchuk, I. V. "Apoptosis activity with pulmonary multidrug-resistant tuberculosis." Thesis, БДМУ, 2020. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/18226.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Resistant Tuberculosis"

1

Bastian, Ivan, and Françoise Portaels, eds. Multidrug-resistant Tuberculosis. Springer Netherlands, 2000. http://dx.doi.org/10.1007/978-94-011-4084-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

N, Rom William, and Garay Stuart M, eds. Tuberculosis. Little, Brown, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

(Geneva), WHO, and Gupta Rajesh, eds. Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). World health organization (WHO), 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nguy, Shui. Drug-resistant tuberculosis: Causes, diagnosis, and treatments. Edited by K'ung Zhou. Nova Science Publishers, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Harvard Medical School. Program in Infectious Disease and Social Change. and Open Society Institute, eds. The global impact of drug-resistant tuberculosis. Program in Infectious Disease and Social Change, Dept. of Social Medicine, Harvard Medical School, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lu, Pu-Xuan, Hong-zhou Lu, and Yong-xiang Yi, eds. Diagnostic Imaging of Drug Resistant Pulmonary Tuberculosis. Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-99-8339-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination. TB elimination: Treatment of drug-resistant tuberculosis. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of Tuberculosis Elimination, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hopkins, Tanne Janice, ed. Timebomb: The global epidemic of multi-drug-resistant tuberculosis. McGraw-Hill, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Dermot, Maher, Chaulet Pierre, and Grosset Jacques, eds. Principes pour la prise en charge de la tuberculose à bacilles résistants. Organisation mondiale de la santé, programme mondial de lutte contre la tuberculose, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Crofton, John. Guidelines for the management of drug-resistant tuberculosis. World Health Organization, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Resistant Tuberculosis"

1

Davies, Peter D. O. "Multi-Drug-Resistant Tuberculosis." In Tuberculosis. Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-642-18937-1_46.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dheda, Keertan, Aliasgar Esmail, Anzaan Dippenaar, Robin Warren, Jennifer Furin, and Christoph Lange. "Drug-Resistant Tuberculosis." In Clinical Tuberculosis. CRC Press, 2020. http://dx.doi.org/10.1201/9781351249980-16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Johnson, Livette S., and Kent A. Sepkowitz. "Treatment of multi-drug-resistant tuberculosis." In Tuberculosis. Springer US, 1995. http://dx.doi.org/10.1007/978-1-4899-2869-6_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Conradie, Francesca. "The Shorter Regimen for Multidrug-Resistant or Rifampicin-Resistant Tuberculosis." In Essential Tuberculosis. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-66703-0_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Liang, Lili, Yun Ma, Xin liu, and Yamin Lv. "Drug-Resistant Tuberculosis." In Drug Resistance in Bacteria, Fungi, Malaria, and Cancer. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-48683-3_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ahmad Khan, Faiz, Greg Fox, and Dick Menzies. "Drug-Resistant Tuberculosis." In Handbook of Antimicrobial Resistance. Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0667-3_13-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ahmad Khan, Faiz, Greg Fox, and Dick Menzies. "Drug-Resistant Tuberculosis." In Handbook of Antimicrobial Resistance. Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-0694-9_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Li, Chun-hua, Jie Zhou, Xian-rong Long, et al. "Multidrug-Resistant Tuberculosis." In Diagnostic Imaging of Drug Resistant Pulmonary Tuberculosis. Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-99-8339-1_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Auld, Sara C., Neel R. Gandhi, and James C. M. Brust. "Drug-Resistant Tuberculosis and HIV." In HIV and Tuberculosis. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-29108-2_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Schluger, Neil W. "Extensively Drug-Resistant Tuberculosis." In Emerging Infections 8. ASM Press, 2014. http://dx.doi.org/10.1128/9781555815592.ch17.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Resistant Tuberculosis"

1

Waghmare, Manoj, Ketaki Utpat, Unnati Desai, and Jyotsna Joshi. "Drug resistant tuberculosis at a drug resistant tuberculosis centre, India- Analysis of outcome." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa2729.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kurnianingsih, Widya, Didik Gunawan Tamtomo, and Bhisma Murti. "Incomplete Medication Intake and Multidrug Resistant Tuberculosis." In The 7th International Conference on Public Health 2020. Masters Program in Public Health, Universitas Sebelas Maret, 2020. http://dx.doi.org/10.26911/the7thicph.01.58.

Full text
Abstract:
Background: Multidrug Resistant Tuberculosis (MDR-TB) is a highest problem in the prevention and eradication of TB worldwide. MDR-TB exists in 27 countries where there are at least 6,800 MDR-TB cases annually and 12% of new TB cases registered are MDR TB. This study aimed to examine the effect of incomplete medication intake on the incidence of MDR TB. Subjects and Method: Meta-analysis and systematic review was conducted by collecting articles from Google Scholar, Pubmed, and Springer Link databases, from year 2010 to 2019. Keywords used “Risk Factor MDR TB” OR “Previous Treatment” AND “Multidrug resistant tuberculosis”. The inclusion criteria were full text, using English language, using case control study design, and reporting adjusted odds ratio. The study population was patients with Tuberculosis. The intervention was incomplete medication intake with comparison complete medication intake. The study outcome was multidrug resistant Tuberculosis. Collected articles were selected by PRISMA flow chart. Quantitative data were analyzed by fixed effect model using Revman 5.3. Results: 6 studies from Taiwan, Bangladesh, Malaysia, and Ethiophia were selected for data analysis. This study reported that incomplete medication intake increased the risk of multidrug resistant tuberculosis (aOR= 14.33; 95% CI= 12.47 to 16.47; p&lt;0.001). Conclusion: Incomplete medication intake increases the risk of multidrug resistant Tuberculosis. Keywords: incomplete medication intake, multidrug resistant tuberculosis Correspondence: Widya Kurnianingsih. Masters Program in Public Health. Universitas Sebelas Maret, Jl. Ir. Sutami 36A, Surakarta 57126, Central Java. Email: widyakurnianingsih08@gmail.com. Mobile: 081556837033
APA, Harvard, Vancouver, ISO, and other styles
3

Ivanova, Diana, Sergey Borisov, Nickolay Nikolenko, and Sergey Kosenkov. "Comorbidome in multidrug-resistant tuberculosis patients." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.479.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Denysov, Aleksey, Lilia Todoriko, Inga Ieremenchuk, and Igor Semianiv. "Cytokine regulation in multidrug-resistant tuberculosis." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa2703.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Semianiv, Ihor, Liliia Todoriko, Inga Yeremenchuk, and Olena Pidverbetska. "Multidrug-resistant tuberculosis and diabetes mellitus." In ERS Congress 2024 abstracts. European Respiratory Society, 2024. http://dx.doi.org/10.1183/13993003.congress-2024.pa2371.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ćurcic, Radmila, Dragana Vukovic, Irena Zivanovic, Ivana Dakic, and Branislava Savic. "Resistance genotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Serbia." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa4632.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hafidh, E. P., N. Aulida, B. D. Handari, and D. Aldila. "Optimal control problem from tuberculosis and multidrug resistant tuberculosis transmission model." In PROCEEDINGS OF THE 3RD INTERNATIONAL SYMPOSIUM ON CURRENT PROGRESS IN MATHEMATICS AND SCIENCES 2017 (ISCPMS2017). Author(s), 2018. http://dx.doi.org/10.1063/1.5064220.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hidayathillah, Ariska Putri, Chatarina Umbul W, and Hari Basuki N. "Index Predictive of Drug Resistant Tuberculosis (MDR-TB) on Tuberculosis Patients." In The 2nd International Symposium of Public Health. SCITEPRESS - Science and Technology Publications, 2017. http://dx.doi.org/10.5220/0007511902270231.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Metcalfe, JZ, A. Cattamanchi, G. Lin, et al. "Transmission of Multidrug Resistant Tuberculosis in California." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a2204.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Carroll, Matthew W., M. S. Lee, T. S. Song, et al. "Linezolid For Extensively Drug Resistant Pulmonary Tuberculosis." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1838.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Resistant Tuberculosis"

1

Yusim, Karina, Bette T. M. Korber, Shihai Feng, and Chang-Shung Tung. Compensatory mutation in RpoC restores fitness to rifampicin-resistant multi-drug resistant Mycobacterium tuberculosis. Office of Scientific and Technical Information (OSTI), 2012. http://dx.doi.org/10.2172/1049993.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Philip Sell, Philip Sell. Developing a novel oxysterol antibiotic to combat drug-resistant tuberculosis. Experiment, 2025. https://doi.org/10.18258/77730.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tumwasorn, Somying, Ajcharaporn Sawatpanich, Nibondh Udomsantisuk, and Kamon Kawkitinarong. Development of test kit for detection of rifampin resistance in mycobacterium tuberculosis by PCR-reverse line blot hybridization. Faculty of Medicine, Chulalongkorn University, 2006. https://doi.org/10.58837/chula.res.2006.25.

Full text
Abstract:
A genetic test by PCR-reverse line blot hybridization was developed for rapid detection of mycobacterium tuberculosis and rifampin resistance simultaneously. Duplex PCR targeting IS 6110 and rpoB gene was employed to detect M. tuberculosis and the rpoB fragment with rifampin resistance hot spot region. The analytical sensitivity of duplex PCR for IS 6110 and rpoB gene was found to be 10 and 100fg of M.Tuberculosis H37Rv DNA, respectively. Since duplex PCR was specific to M. tuberculosis complex, it was thus able to be applied directly in clinical specimens. Oligonucleotide probes were designed to detect wild-type and mutant genotypes of rpoB gene. These probes together with an M. tuberculosis specific probe were blotted in parallel lines in a membrane strip and used for hybridization with PCR product amplified from clinical isolates and sputum specimens. The developed test was able to detect M. tuberculosis clinical isolates with known rpoB gene sequences and the presence of M. tuberculosis in 98.75% (79/80) of sputum specimens. When the amplified products were subjected to reverse line blot hybridization, the test detected 85.71% (24/28) of rifampin-resistant and all rifampin sensitive M. tuberculosis in sputums specimens. The clinical sensitivity and specificity of the test for rifampin resistance was 85.7% and 100%, respectively. Considering the turnaround time, cost and shelf life of the test, duplex PCR-reverse line blot hybridization offers a potential of the test kit for detection of frequent mutations leading to rifampin resistance in clinical laboratories.
APA, Harvard, Vancouver, ISO, and other styles
4

Lau, J., and B. Baker. Isothermal DNA Assay to Detect Drug-Resistant Tuberculosis for Point-of-Care Diagnostics. Office of Scientific and Technical Information (OSTI), 2013. http://dx.doi.org/10.2172/1093910.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nahas, Kamal. The Long Road to End Tuberculosis. Asimov Press, 2024. http://dx.doi.org/10.62211/85pr-22fg.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mahkota, Renti, and Mathuros Tipayamongkholgul. Epidemiology of Tuberculosis and Multidrug-Resistance Tuberculosis In Indonesia: A Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.9.0016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lewin, Simon, and Peter Steinmann. Do material incentives improve patient adherence in tuberculosis? SUPPORT, 2017. http://dx.doi.org/10.30846/1704152.

Full text
Abstract:
Adherence to treatment for tuberculosis (TB) is frequently sub-optimal. However, good adherence is important for successful treatment and to minimize the risk of drug resistance. Adherence is also essential for different components of TB prophylaxis. Material incentives for patients to encourage them to take their treatment as prescribed, or to assist them in overcoming financial barriers to treatment, have been suggested as interventions to improve TB treatment adherence.
APA, Harvard, Vancouver, ISO, and other styles
8

Rapid tests for diagnosing drug resistant tuberculosis are accurate and may be cost effective. National Institute for Health Research, 2015. http://dx.doi.org/10.3310/signal-000145.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tuberculosis farmacorresistente. Instituto Nacional de Salud, 2022. http://dx.doi.org/10.33610/infoeventos.33.

Full text
Abstract:
La bacteria causante de la tuberculosis (TB) puede volverse resistente a los antimicrobianos utilizados para curar la enfermedad. La resistencia a los medicamentos aparece como consecuencia de un uso indebido de los antibióticos al tratar con ellos a pacientes afectados de tuberculosis farmacosensible.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Resistant Tuberculosis' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography